Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability

Three 18F-labeled radiopharmaceuticals have been Food and Drug Administration-approved for the identification of cortical amyloidosis in clinical settings. Although there has been strong debate among professionals as to the ethical and social consequences of disclosing such information, increasing numbers of participants are being recruited into secondary prevention trials for which Read & Research Alzheimer’s More

Leave a Reply